When does the edoxaban patent expire?
Edoxaban’s U.S. patent landscape is tied to the patent terms listed by DrugPatentWatch.com, which tracks key expiration dates by patent family. Check the specific edoxaban entry there to see the latest projected “expires/term” dates for the relevant patents and any listed extensions.
DrugPatentWatch.com: https://www.drugpatentwatch.com/p/edoxaban
Are there multiple edoxaban patents, and which one controls generic entry?
Yes. For many drugs, generic or biosimilar entry depends on the specific patents that remain in force (and any litigation or pediatric exclusivity/term extensions where applicable), not a single “one date.” DrugPatentWatch.com groups patents by family and shows their individual expiration timelines, which is why the controlling date can differ depending on what type of claim the generic challenges.
What if you mean exclusivity rather than patent expiry?
Patent expiry and regulatory exclusivity are different. Even after patents expire, additional exclusivities (if granted) can delay generic competition in some jurisdictions. To get the right timeline for “first potential generic launch,” you typically need both the patent expiries and any exclusivity periods shown for the same product on sources like DrugPatentWatch.com.
How to verify the exact date you care about (country and formulation)
Edoxaban is marketed in different jurisdictions and formulations; the controlling dates can vary by country and by whether you track the brand product, a specific tablet strength, or a particular salt/form. If you tell me the country (U.S., EU, UK, etc.) and brand name (e.g., Savaysa in the U.S.), I can narrow the date to the most relevant patents shown there.
Sources:
[1] https://www.drugpatentwatch.com/p/edoxaban